Celgene (CELG) Partner Acceleron Initiates ACE-536 Phase 2
Acceleron Pharma, Inc., announced the initiation of a phase 2 study of its novel, investigational protein therapeutic, ACE-536, to treat patients with beta-thalassemia, a genetic hematologic disorder causing chronic and life-threatening anemia and serious complications affecting the spleen, liver and heart. Patients and healthcare providers currently have limited options for the treatment of beta-thalassemia. This is the second ongoing Phase 2 trial for ACE-536, which is being developed by Acceleron as part of a global collaboration with Celgene Corporation (Nasdaq: CELG).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cardiovascular Systems (CSII) Offers Three-Year Data from Pivotal ORBIT II Study
- Zumiez, Inc. (ZUMZ) April 2016 Comps Fell 6%
- Metaldyne Performance Group (MPG) to Wind-Down Wheel Bearing Business
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!